(Reuters) - The U.S. Food and Drug Administration has declined to reduce the severity of its warning about neuropsychiatric side effects associated with Pfizer Inc's quit-smoking drug Chantix, the agency said on Monday. The decision follows the recommendation of an advisory committee, which voted last October to keep information about the drug's psychiatric risks, including suicidal thoughts, hostility and agitation, highlighted inside a black box on the package label. Chantix, known chemically as varenicline, was approved in 2006. Pfizer subsequently submitted data that it said showed the drug was not associated with severe psychiatric side effects.
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/1KN1w2g
No comments:
Post a Comment